Myriad Genetics Inc
MYGN8.180USD
+0.140+1.74%
Close 11/03, 16:00（ET）Quotes delayed by 15 min
761.56MMarket Cap
LossP/E TTM
More Details of Myriad Genetics Inc Company
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.
Myriad Genetics Inc Info
Ticker SymbolMYGN
Company nameMyriad Genetics Inc
IPO dateOct 06, 1995
CEOMr. Samraat S. (Sam) Raha
Number of employees2700
Security typeOrdinary Share
Fiscal year-endOct 06
Address322 North 2200 West
CitySALT LAKE CITY
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code84116
Phone18015843600
Websitehttps://myriad.com/
Ticker SymbolMYGN
IPO dateOct 06, 1995
CEOMr. Samraat S. (Sam) Raha
Company Executives of Myriad Genetics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
220.57K
-0.49%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-0.74%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Mr. Benjamin Richard (Ben) Wheeler
Mr. Benjamin Richard (Ben) Wheeler
Chief Financial Officer
Chief Financial Officer
92.65K
-2.69%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
45.88K
-46.96%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matt Scalo
Mr. Matt Scalo
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
220.57K
-0.49%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-0.74%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Hereditary Cancer
96.30M
45.19%
Prenatal
47.60M
22.34%
Pharmacogenomics
37.80M
17.74%
Tumor Profiling
31.40M
14.73%
By RegionUSD
Name
Revenue
Proportion
United States
198.20M
93.01%
Rest of world
14.90M
6.99%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Hereditary Cancer
96.30M
45.19%
Prenatal
47.60M
22.34%
Pharmacogenomics
37.80M
17.74%
Tumor Profiling
31.40M
14.73%
Shareholding Stats
Updated: Wed, Oct 8
Updated: Wed, Oct 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.43%
The Vanguard Group, Inc.
8.47%
Millennium Management LLC
5.29%
State Street Investment Management (US)
5.17%
Glenview Capital Management, LLC
4.93%
Other
61.70%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.43%
The Vanguard Group, Inc.
8.47%
Millennium Management LLC
5.29%
State Street Investment Management (US)
5.17%
Glenview Capital Management, LLC
4.93%
Other
61.70%
Shareholder Types
Shareholders
Proportion
Investment Advisor
37.21%
Hedge Fund
27.56%
Investment Advisor/Hedge Fund
25.31%
Research Firm
6.02%
Individual Investor
3.32%
Pension Fund
1.88%
Bank and Trust
0.41%
Venture Capital
0.31%
Family Office
0.08%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
515
91.89M
98.76%
-9.78M
2025Q2
518
100.80M
108.34%
-1.85M
2025Q1
527
99.14M
107.57%
-4.54M
2024Q4
516
96.89M
106.12%
-1.41M
2024Q3
505
95.02M
104.61%
-5.50M
2024Q2
486
96.79M
106.52%
-6.22M
2024Q1
460
98.19M
108.68%
+613.48K
2023Q4
464
93.46M
105.77%
+2.70M
2023Q3
471
86.01M
104.78%
-3.73M
2023Q2
480
84.60M
103.32%
-6.34M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
13.43M
14.43%
-416.99K
-3.01%
Jun 30, 2025
The Vanguard Group, Inc.
9.15M
9.83%
-1.47M
-13.83%
Jun 30, 2025
Millennium Management LLC
4.92M
5.29%
+855.19K
+21.01%
Jun 30, 2025
State Street Investment Management (US)
4.81M
5.17%
-458.84K
-8.71%
Jun 30, 2025
Glenview Capital Management, LLC
4.59M
4.93%
+687.86K
+17.64%
Jun 30, 2025
D. E. Shaw & Co., L.P.
4.51M
4.85%
+1.99M
+78.84%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.37M
3.63%
+1.97M
+140.14%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.22M
2.39%
-7.80K
-0.35%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.07M
2.23%
-139.99K
-6.33%
Jun 30, 2025
Qube Research & Technologies Ltd
2.05M
2.21%
+633.44K
+44.67%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
WisdomTree BioRevolution Fund
0.81%
Federated Hermes MDT Small Cap Core ETF
0.74%
Global X Genomics & Biotechnology ETF
0.74%
Invesco NASDAQ Future Gen 200 ETF
0.55%
Invesco S&P SmallCap Health Care ETF
0.43%
Inspire Small/Mid Cap ESG ETF
0.26%
Strategas Global Policy Opportunities ETF
0.23%
SPDR S&P Biotech ETF
0.21%
Vanguard US Quality Factor ETF
0.13%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.12%
View more
WisdomTree BioRevolution Fund
Proportion0.81%
Federated Hermes MDT Small Cap Core ETF
Proportion0.74%
Global X Genomics & Biotechnology ETF
Proportion0.74%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.55%
Invesco S&P SmallCap Health Care ETF
Proportion0.43%
Inspire Small/Mid Cap ESG ETF
Proportion0.26%
Strategas Global Policy Opportunities ETF
Proportion0.23%
SPDR S&P Biotech ETF
Proportion0.21%
Vanguard US Quality Factor ETF
Proportion0.13%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
